Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review

Date: July 5, 2016
Pages: 39
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: LBD799AA218EN
Leaflet:

Download PDF Leaflet

Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review
Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases. It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as solid tumors, acute ischemia and Gaucher’s disease, among others. Its lead compound, LB-100 is being developed in Phase I clinical trials. Lixte established a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.

Lixte Biotechnology Holdings, Inc. Key Recent Developments

Jun 07, 2016: Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Lixte Biotechnology Holdings, Inc. - Key Facts
Lixte Biotechnology Holdings, Inc. - Key Employees
Lixte Biotechnology Holdings, Inc. - Key Employee Biographies
Lixte Biotechnology Holdings, Inc. - Major Products and Services
Lixte Biotechnology Holdings, Inc. - Pharmaceutical Pipeline Products Data
Lixte Biotechnology Holdings, Inc., Pipeline Products by Therapy Area
Lixte Biotechnology Holdings, Inc., Pipeline Products by Development Phase
Lixte Biotechnology Holdings, Inc. - History
Lixte Biotechnology Holdings, Inc. - Company Statement
Lixte Biotechnology Holdings, Inc. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Lixte Biotechnology Holdings, Inc. - Business Description
Lixte Biotechnology Holdings, Inc. - Corporate Strategy
Lixte Biotechnology Holdings, Inc. - SWOT Analysis
SWOT Analysis - Overview
Lixte Biotechnology Holdings, Inc. - Strengths
Strength - Diversified Markets
Strength - Internal Research Programs
Strength - Proprietary Pharmacological Agents
Lixte Biotechnology Holdings, Inc. - Weaknesses
Weakness - Lack of Commercial Products
Weakness - Higher Cost Structure
Lixte Biotechnology Holdings, Inc. - Opportunities
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - HER2-Positive Breast Cancer in the US
Opportunity - Changing Demographics
Lixte Biotechnology Holdings, Inc. - Threats
Threat - Intellectual Property Risk
Threat - Competitive Pressures
Threat - Reliance on Third Party Manufacturers
Lixte Biotechnology Holdings, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Lixte Biotechnology Holdings, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 07, 2016: Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Lixte Biotechnology Holdings, Inc., Key Facts
Lixte Biotechnology Holdings, Inc., Key Employees
Lixte Biotechnology Holdings, Inc., Key Employee Biographies
Lixte Biotechnology Holdings, Inc., Major Products and Services
Lixte Biotechnology Holdings, Inc., Number of Pipeline Products by Therapy Area
Lixte Biotechnology Holdings, Inc., Number of Pipeline Products by Development Stage
Lixte Biotechnology Holdings, Inc., Pipeline Products By Therapy Area and Development Phase
Lixte Biotechnology Holdings, Inc., History
Lixte Biotechnology Holdings, Inc., Key Competitors
Lixte Biotechnology Holdings, Inc., Ratios based on current share price
Lixte Biotechnology Holdings, Inc., Annual Ratios
Lixte Biotechnology Holdings, Inc., Interim Ratios
Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Lixte Biotechnology Holdings, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Lixte Biotechnology Holdings, Inc., Pipeline Products by Therapy Area
Lixte Biotechnology Holdings, Inc., Pipeline Products by Development Phase
Lixte Biotechnology Holdings, Inc., Performance Chart (2011 - 2015)
Lixte Biotechnology Holdings, Inc., Ratio Charts
Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Lixte Biotechnology Holdings, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: